Harnessing neoantigen specific CD4 T cells for cancer immunotherapy.

Brightman, Spencer E; Naradikian, Martin S; Miller, Aaron M; Schoenberger, Stephen P

Brightman, Spencer E; Naradikian, Martin S; Miller, Aaron M; Schoenberger, Stephen P.

Affiliation

Brightman SE; La Jolla Institute for Immunology, La Jolla, California, USA.
Naradikian MS; La Jolla Institute for Immunology, La Jolla, California, USA.
Miller AM; La Jolla Institute for Immunology, La Jolla, California, USA.
Schoenberger SP; La Jolla Institute for Immunology, La Jolla, California, USA.

J Leukoc Biol ; 107(4): 625-633, 2020 04.

Article in En | MEDLINE | ID: mdl-32170883

Subject(s)

Antigens, Neoplasm/metabolism; Immunotherapy; Neoplasms/immunology; Neoplasms/therapy; Animals; CD4-Positive T-Lymphocytes/immunology; Cancer Vaccines/immunology; Humans; T-Lymphocytes, Helper-Inducer/immunology

Key words

adoptive cell therapy; cancer vaccines; immune checkpoint blockade; neoantigens

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunotherapy / Antigens, Neoplasm / Neoplasms Limits: Animals / Humans Language: En Journal: J Leukoc Biol Year: 2020 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google